{
    "2020-03-21": [
        [
            {
                "time": "",
                "original_text": "【民生医药|周报】原料药跑赢板块，继续推荐全球产业链定价能力强和内需驱动的医药细分龙头",
                "features": {
                    "keywords": [
                        "原料药",
                        "跑赢板块",
                        "全球产业链",
                        "定价能力",
                        "内需驱动",
                        "医药细分龙头"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "三明联盟出手、上海“4+7”续约，仿制药价格再创新低！带量采购下，仿制药还有投资空间吗？",
                "features": {
                    "keywords": [
                        "三明联盟",
                        "4+7续约",
                        "仿制药",
                        "价格新低",
                        "带量采购",
                        "投资空间"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}